| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 35, 1380-1384, Copyright © 1989 by American Association for Clinical Chemistry
C Labeur, G Michiels, J Bury, DC Usher and M Rosseneu
Department of Clinical Chemistry, Brugge, Belgium.
This new, sensitive, specific "sandwich"-type enzyme-linked immunosorbent assay (ELISA) for quantifying lipoprotein(a) [Lp(a)] in human serum and in ultracentrifugal lipoprotein fractions is based on use of a monoclonal antibody raised against apolipoprotein(a) as coating protein and a polyclonal antibody, raised against either apo B or against Lp(a) and conjugated with peroxidase, for detection of bound Lp(a). Mean intra- and interassay CVs for assay of 16 samples were 3.0% and 5.6%, respectively. Sample pretreatment with urea did not enhance Lp(a) immunoreactivity, and treatment with nonionic detergents decreased binding to the monoclonal antibody. Results correlated well (r = 0.99, n = 38) with those by radial immunodiffusion (RID). The ELISA assay, however, detects amounts corresponding to Lp(a) contents of 10 to 1000 mg/L in plasma samples diluted 1000-fold, compared with 100-500 mg/L for RID. For 92 normolipidemic subjects, the mean Lp(a) concentration was 120 (SD 130) mg/L. In patients undergoing coronary angiography, Lp(a) concentrations increased with the severity of the disease but were not correlated with either HDL cholesterol, triglycerides, apo A-I, or apo B, and only weakly with plasma cholesterol and apo A-II. These two correlations were even weaker in normal subjects, and only the correlation with total cholesterol was valid. Lp(a), measured at birth and at seven days and six months, steadily increased with age. This assay is well suited for measuring Lp(a) in plasma and in lipoprotein fractions and also for screening programs evaluating this significant genetic risk factor for the development of atherosclerosis.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  B. Smolders, R. Lemmens, and V. Thijs Lipoprotein (a) and Stroke: A Meta-Analysis of Observational Studies Stroke, June 1, 2007; 38(6): 1959 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D Tsironis, J. V Mitsios, H. J Milionis, M. Elisaf, and A. D Tselepis Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase Cardiovasc Res, July 1, 2004; 63(1): 130 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Klausen, U. Beisiegel, H.-J. Menzel, M. Rosseneu, V. Nicaud, and O. Faergeman Apo(a) Phenotypes and Lp(a) Concentrations in Offspring of Men With and Without Myocardial Infarction : The EARS Study Arterioscler Thromb Vasc Biol, August 1, 1995; 15(8): 1001 - 1008. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Nogues, M. Seni, J. Pedro-Botet, J. Rubies-Prat, and F. Vidal-Barraquer Serum Lipoprotein (a) Levels in Men with Peripheral Vascular Disease Angiology, August 1, 1991; 42(8): 659 - 664. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
